Antidiabetic Effects on Intrahepatic Fat

PHASE4CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

October 31, 2015

Conditions
Non-Alcoholic Fatty Liver DiseaseType2 Diabetes
Interventions
DRUG

Liraglutide

the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study

DRUG

Metformin

the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study

DRUG

Gliclazide

the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of \<7.0 mmol/L

Trial Locations (1)

210008

at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT03068065 - Antidiabetic Effects on Intrahepatic Fat | Biotech Hunter | Biotech Hunter